Company that develops continued glucose monitoring systems (usually pain-free watches) for diabetes.
The maker of continuous glucose monitoring (CGM) systems. Shares up 50% this year. Joined the S and P 500 in May. Looks a good long term buy.
Dexcom Q3 Earnings Beat Street, Raises FY21 Outlook Ahead Of G7 Launch
Q3 adjusted EPS of $0.89] though lower than $0.94 posted a year ago, came in sharply above the consensus of $0.63.
- Sales increased 30% Y/Y to $650.20 million, surpassing the consensus of $617.82 million.
- Volume growth and strong new customer additions continue to be the primary driver of revenue growth as awareness of real-time Continuous Glucose Monitoring (CGM) increases.
- The Company achieved an adjusted gross margin of 68.7% versus 68% a year ago.
- Adjusted operating income increased from $95 million to $123.8 million.
- Dexcom ended Q3 with $2.70 billion in cash, cash equivalents, and marketable securities.
- “We are pleased to once again be in a position to raise our full-year revenue and margin guidance as we drive toward a strong conclusion of 2021 and the upcoming launch of our Dexcom G7 system,” said Kevin Sayer, Chairman, President & CEO.
- Guidance: Dexcom forecasts revenue of $2.425 billion - 2.450 billion (consensus of $2.4 billion) compared to prior guidance of $2.35 billion - $2.4 billion.
1 Like
My daughter now has the G7 continuous monitor with the app and I have to say it’s impressive!
Just saying,